IL1B and metabolic dysfunction-associated steatohepatitis: These include an analysis of the effect of the P2X7R inhibitor SGM-1019 in NASH, two trials with the recombinant IL-1 receptor antagonist anakinra in AH, and the utility of the IL-1β blocking antibody canakinumab in AH (Table 1).